Recent insights into cell surface heparan sulphate proteoglycans and cancer.

F1000Research

Volumn 5, Issue , 2016, Pages

  Couchman, John R ^a   Multhaupt, Hinke ^a   Sanderson, Ralph D ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; PROTEOHEPARAN SULFATE; SYNDECAN;

ACTIN FILAMENT; CELL ADHESION; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; EXOSOME; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PARACRINE SIGNALING; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

EID: 85010957537     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8543.1     Document Type: Review

References (84)

1. Aspberg A: The different roles of aggrecan interaction domains. J Histochem Cytochem. 2012; 60(12): 987-96.
2. Heinegård D, Saxne T: The role of the cartilage matrix in osteoarthritis. Nat Rev Rheumatol. 2011; 7(1): 50-6.
3. Neill T, Schaefer L, Iozzo RV: Decoding the Matrix: Instructive Roles of Proteoglycan Receptors. Biochemistry. 2015; 54(30): 4583-98.
4. Iozzo RV, Sanderson RD: Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011; 15(5): 1013-31.
5. Couchman JR: Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol. 2010; 26: 89-114.
6. Pickford CE, Holley RJ, Rushton G, et al.: Specific glycosaminoglycans modulate neural specification of mouse embryonic stem cells. Stem Cells. 2011; 29(4): 629-40.
7. Schaefer L, Iozzo RV: Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev. 2012; 22(1): 56-7.
8. Multhaupt HA, Leitinger B, Gullberg D, et al.: Extracellular matrix component signaling in cancer. Adv Drug Deliv Rev. 2016; 97: 28-40.
9. Theocharis AD, Gialeli C, Bouris P, et al.: Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J. 2014; 281(22): 5023-42.
10. Filmus J, Capurro M, Rast J: Glypicans. Genome Biol. 2008; 9(5): 224.
11. Morgan MR, Humphries MJ, Bass MD: Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol. 2007; 8(12): 957-69.
12. Couchman JR, Gopal S, Lim HC, et al.: Syndecans: from peripheral coreceptors to mainstream regulators of cell behaviour. Int J Exp Pathol. 2015; 96(1): 1-10.
13. Multhaupt HA, Couchman JR: Heparan sulfate biosynthesis: methods for investigation of the heparanosome. J Histochem Cytochem. 2012; 60(12): 908-15.
14. Xu D, Esko JD: Demystifying heparan sulfate-protein interactions. Annu Rev Biochem. 2014; 83: 129-57.
15. Gallagher J: Fell-Muir Lecture: Heparan sulphate and the art of cell regulation: a polymer chain conducts the protein orchestra. Int J Exp Pathol. 2015; 96(4): 203-31.
16. Lindahl U, Li JP: Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol. 2009; 276: 105-59.
17. Lamanna WC, Kalus I, Padva M, et al.: The heparanome-the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol. 2007; 129(2): 290-307.
18. Rosen SD, Lemjabbar-Alaoui H: Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets. 2010; 14(9): 935-49.
19. Hammond E, Khurana A, Shridhar V, et al.: The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. Front Oncol. 2014; 4: 195.
20. Bernfield M, Götte M, Park PW, et al.: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999; 68: 729-77.
21. Poluzzi C, Iozzo RV, Schaefer L: Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers. Adv Drug Deliv Rev. 2016; 97: 156-73.
22. Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007; 446(7139): 1030-7.
23. Jung O, Trapp-Stamborski V, Purushothaman A, et al.: Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis. 2016; 5: e202.
24. Zhang L, Ngo JA, Wetzel MD, et al.: Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia. 2015; 17(1): 101-13.
25. Ramani VC, Zhan F, He J, et al.: Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016; 7(2): 1598-607.
26. Wu L, Viola CM, Brzozowski AM, et al.: Structural characterization of human heparanase reveals insights into substrate recognition. Nat Struct Mol Biol. 2015; 22(12): 1016-22.
27. Weissmann M, Arvatz G, Horowitz N, et al.: Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2016; 113(3): 704-9.
28. Jakobsson L, Kreuger J, Holmborn K, et al.: Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell. 2006; 10(5): 625-34.
29. Matsuo I, Kimura-Yoshida C: Extracellular modulation of Fibroblast Growth Factor signaling through heparan sulfate proteoglycans in mammalian development. Curr Opin Genet Dev. 2013; 23(4): 399-407.
30. Peysselon F, Ricard-Blum S: Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol. 2014; 35: 73-81.
31. Vivès RR, Seffouh A, Lortat-Jacob H: Post-Synthetic Regulation of HS Structure: The Yin and Yang of the Sulfs in Cancer. Front Oncol. 2014; 3: 331.
32. Yang JD, Sun Z, Hu C, et al.: Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer. 2011; 50(2): 122-35.
33. Lamanna WC, Frese MA, Balleininger M, et al.: Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem. 2008; 283(41): 27724-35.
34. Lai JP, Sandhu DS, Yu C, et al.: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology. 2008; 47(4): 1211-22.
35. Baietti MF, Zhang Z, Mortier E, et al.: Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012; 14(7): 677-85.
36. Grootjans JJ, Zimmermann P, Reekmans G, et al.: Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. Proc Natl Acad Sci U S A. 1997; 94(25): 13683-8.
37. Das SK, Bhutia SK, Kegelman TP, et al.: MDA-9/syntenin: a positive gatekeeper of melanoma metastasis. Front Biosci (Landmark Ed). 2012; 17: 1-15.
38. Ghossoub R, Lembo F, Rubio A, et al.: Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. Nat Commun. 2014; 5: 3477.
39. Théry C, Boussac M, Véron P, et al.: Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001; 166(12): 7309-18.
40. Friand V, David G, Zimmermann P: Syntenin and syndecan in the biogenesis of exosomes. Biol Cell. 2015; 107(10): 331-41.
41. Kashyap R, Roucourt B, Lembo F, et al.: Syntenin controls migration, growth, proliferation, and cell cycle progression in cancer cells. Front Pharmacol. 2015; 6: 241.
42. Escola JM, Kleijmeer MJ, Stoorvogel W, et al.: Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 1998; 273(32): 20121-7.
43. Kegelman TP, Das SK, Emdad L, et al.: Targeting tumor invasion: the roles of MDA-9/Syntenin. Expert Opin Ther Targets. 2015; 19(1): 97-112.
44. Thompson CA, Purushothaman A, Ramani VC, et al.: Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013; 288(14): 10093-9.
45. Roucourt B, Meeussen S, Bao J, et al.: Heparanase activates the syndecansyntenin-ALIX exosome pathway. Cell Res. 2015; 25(4): 412-28.
46. Purushothaman A, Bandari SK, Liu J, et al.: Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. J Biol Chem. 2016; 291(4): 1652-63.
47. Christianson HC, Svensson KJ, van Kuppevelt TH, et al.: Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci U S A. 2013; 110(43): 17380-5.
48. Melo SA, Luecke LB, Kahlert C, et al.: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523(7559): 177-82.
49. Greene DK, Tumova S, Couchman JR, et al.: Syndecan-4 associates with alphaactinin. J Biol Chem. 2003; 278(9): 7617-23.
50. Choi Y, Kim S, Lee J, et al.: The oligomeric status of syndecan-4 regulates syndecan-4 interaction with alpha-actinin. Eur J Cell Biol. 2008; 87(10): 807-15.
51. Okina E, Grossi A, Gopal S, et al.: Alpha-actinin interactions with syndecan-4 are integral to fibroblast-matrix adhesion and regulate cytoskeletal architecture. Int J Biochem Cell Biol. 2012; 44(12): 2161-74.
52. Dovas A, Yoneda A, Couchman JR: PKCbeta-dependent activation of RhoA by syndecan-4 during focal adhesion formation. J Cell Sci. 2006; 119(Pt 13): 2837-46.
53. Bass MD, Roach KA, Morgan MR, et al.: Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix. J Cell Biol. 2007; 177(3): 527-38.
54. Hall A: Rho family GTPases. Biochem Soc Trans. 2012; 40(6): 1378-82.
55. Li H, Peyrollier K, Kilic G, et al.: Rho GTPases and cancer. Biofactors. 2014; 40(2): 226-35.
56. Gopal S, Bober A, Whiteford JR, et al.: Heparan sulfate chain valency controls syndecan-4 function in cell adhesion. J Biol Chem. 2010; 285(19): 14247-58.
57. Mostafavi-Pour Z, Askari JA, Parkinson SJ, et al.: Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. J Cell Biol. 2003; 161(1): 155-67.
58. Gopal S, Søgaard P, Multhaupt HA, et al.: Transmembrane proteoglycans control stretch-activated channels to set cytosolic calcium levels. J Cell Biol. 2015; 210(7): 1199-211.
59. Reijmers RM, Spaargaren M, Pals ST: Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. FEBS J. 2013; 280(10): 2180-93.
60. Rapraeger AC: Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J. 2013; 280(10): 2207-15.
61. Ramani VC, Purushothaman A, Stewart MD, et al.: The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013; 280(10): 2294-306.
62. Theocharis AD, Skandalis SS, Neill T, et al.: Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta. 2015; 1855(2): 276-300.
63. Barbareschi M, Maisonneuve P, Aldovini D, et al.: High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003; 98(3): 474-83.
64. Leivonen M, Lundin J, Nordling S, et al.: Prognostic value of syndecan-1 expression in breast cancer. Oncology. 2004; 67(1): 11-8.
65. Lim HC, Multhaupt HA, Couchman JR: Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells. Mol Cancer. 2015; 14: 15.
66. Ryu HY, Lee J, Yang S, et al.: Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem. 2009; 284(51): 35692-701.
67. Khotskaya YB, Dai Y, Ritchie JP, et al.: Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem. 2009; 284(38): 26085-95.
68. Ramani VC, Sanderson RD: Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 2014; 35: 215-22.
69. Filmus J, Capurro M: Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013; 280(10): 2471-6.
70. Capurro M, Martin T, Shi W, et al.: Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci. 2014; 127(Pt 7): 1565-75.
71. Haruyama Y, Kataoka H: Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2016; 22(1): 275-83.
72. Capurro M, Wanless IR, Sherman M, et al.: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125(1): 89-97.
73. Iglesias BV, Centeno G, Pascuccelli H, et al.: Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol. 2008; 23(11): 1333-40.
74. Yamauchi N, Watanabe A, Hishinuma M, et al.: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005; 18(12): 1591-8.
75. Pilia G, Hughes-Benzie RM, MacKenzie A, et al.: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996; 12(3): 241-7.
76. Lai JP, Oseini AM, Moser CD, et al.: The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology. 2010; 52(5): 1680-9.
77. Zittermann SI, Capurro MI, Shi W, et al.: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 2010; 126(6): 1291-301.
78. Gao W, Kim H, Ho M: Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One. 2015; 10(9): e0137664.
79. Venning FA, Wullkopf L, Erler JT: Targeting ECM Disrupts Cancer Progression. Front Oncol. 2015; 5: 224.
80. Stewart MD, Ramani VC, Sanderson RD: Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk. J Biol Chem. 2015; 290(2): 941-9.
81. Oikari LE, Okolicsanyi RK, Qin A, et al.: Cell surface heparan sulfate proteoglycans as novel markers of human neural stem cell fate determination. Stem Cell Res. 2016; 16(1): 92-104.
82. Armulik A, Genové G, Betsholtz C: Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011; 21(2): 193-215.
83. Beard RE, Zheng Z, Lagisetty KH, et al.: Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer. 2014; 2: 25.
84. Campoli M, Ferrone S, Wang X: Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res. 2010; 109: 73-121.